Why there's no KLOW peptide dosage chart here
An amount can tell you what's in a preparation. It can't tell you what fits a person.

The missing study comes first
No controlled human study has established a KLOW dosage schedule. The four ingredients have separate research histories. Their study amounts don't add up to a tested schedule for the blend.
A listing may print very precise numbers. Precision describes the contents; it doesn't supply the missing evidence. I want to know whether the actual combination was studied before a number starts to look like an answer.
One small study, in its own setting
The 2025 intravenous BPC-157 pilot gave participants 10 mg on the first day, followed by 20 mg the next day. Intravenous means delivered into a vein. This was BPC-157 alone, not KLOW.
Only two adults took part. The report described no observed adverse events, but a study that small and short can't establish long-term safety or find rare harms. Its amounts are study details, with no personal directions attached.
How it was given matters
The KPV mouse study used drinking water. Its cell experiments used cells grown in a lab. Neither provides a way to calculate a human injection schedule.
Human evidence needs its route kept, too. FDA reviewed a BPC-157 enema study in ulcerative colitis, a bowel disease, and found too little evidence for safety and benefit. Changing the route changes the question.
There is no approved KLOW label to copy
KLOW has no FDA-approved combination product or approved prescribing label. A compounded preparation doesn't gain FDA approval when a clinician prescribes it. A prescription doesn't settle whether its ingredients are eligible for compounding, either.
FDA's July 2026 reviews of BPC-157, KPV and TB-500 explain why a prescription alone isn't enough. Those ingredients don't meet the usual requirements for patient-specific pharmacy compounding. Staff proposed leaving them off the ingredient list, too. Those proposals aren't final decisions. A withdrawn nomination isn't permission to compound.
A care conversation starts with you
A licensed clinician considers the health problem, medical history, other treatments and uncertainties. That review can end without a prescription. A search term doesn't establish eligibility for care.
Location matters too. HHS explains that authorization to practise depends on where the patient is, with state requirements and exceptions. An online listing can't settle that part of the conversation either.
Leave the calculator aside
This guide has no mixing instructions, syringe conversions or cycles for personal use. What it can do is help you read an amount in context. The study's substance, route and subjects belong beside it.
Useful questions for a conversation include: what evidence supports this preparation for this problem? What alternatives have stronger evidence? What risks remain unknown? The research page and ingredient guide give those questions a place to start.